Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.

Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G, FIDELIO-DKD and FIGARO-DKD Investigators

Open source

DOI: 10.2215/cjn.0000000000000149
Published: 2023 May 1
Container: Clinical journal of the American Society of Nephrology : CJASN
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2215/cjn.0000000000000149,
  title = {Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.},
  author = {Sarafidis P and Agarwal R and Pitt B and Wanner C and Filippatos G and Boletis J and Tuttle KR and Ruilope LM and Rossing P and Toto R and Anker SD and Liu ZH and Joseph A and Ahlers C and Brinker M and Lawatscheck R and Bakris G and FIDELIO-DKD and FIGARO-DKD Investigators},
  year = {2023},
  journal = {Clinical journal of the American Society of Nephrology : CJASN},
  doi = {10.2215/cjn.0000000000000149},
  url = {https://doi.org/10.2215/cjn.0000000000000149}
}

RIS

TY  - JOUR
TI  - Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
AU  - Sarafidis P
AU  - Agarwal R
AU  - Pitt B
AU  - Wanner C
AU  - Filippatos G
AU  - Boletis J
AU  - Tuttle KR
AU  - Ruilope LM
AU  - Rossing P
AU  - Toto R
AU  - Anker SD
AU  - Liu ZH
AU  - Joseph A
AU  - Ahlers C
AU  - Brinker M
AU  - Lawatscheck R
AU  - Bakris G
AU  - FIDELIO-DKD and FIGARO-DKD Investigators
PY  - 2023
JO  - Clinical journal of the American Society of Nephrology : CJASN
DO  - 10.2215/cjn.0000000000000149
UR  - https://doi.org/10.2215/cjn.0000000000000149
ER  -

APA

P, S., R, A., B, P., C, W., G, F., J, B., KR, T., LM, R., P, R., R, T., SD, A., ZH, L., A, J., C, A., M, B., R, L., G, B., & Investigators, F. A. F. (2023). Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.. Clinical journal of the American Society of Nephrology : CJASN. https://doi.org/10.2215/cjn.0000000000000149

Source records

pubmed · retrieved 2026-09-26T16:32:05.424Z